by Maria Zannes | Oct 9, 2024 | Press Releases
Noninvasive diagnostic test for lung cancer available to U.S. Veterans, other federal health services patients SAN ANTONIO, TX (Oct. 9, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for...
by Maria Zannes | Sep 18, 2024 | Press Releases
Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis Study by BAMC’s Michael Morris, M.D., and VA’s Sheila Habib, M.D., evaluated...
by Maria Zannes | Sep 18, 2024 | Publications
Journal of Health Economics and Outcomes Research, September 17, 2024 Authors: Morris M.J., Habib S.A., Do Valle M.L., Schneider J.E. Abstract Background: Early detection of lung cancer is crucial for improving patient outcomes. Although advances in diagnostic...
by Maria Zannes | Aug 23, 2024 | Press Releases
Edwards held CFO position at bioAffinity for nine years, leading Company through successful IPO SAN ANTONIO, TX (Aug. 23, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection...
by Maria Zannes | Aug 14, 2024 | Press Releases
bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales Q2 CyPath® Lung test sales up 217% over Q1 2024 Expanded CyPath® Lung test sales to physicians in California and Ohio; now receiving orders from physicians in eight...
